4.7 Review

The emerging role of long non-coding RNAs in renal cell carcinoma progression and clinical therapy via targeting metabolic regulation

期刊

FRONTIERS IN PHARMACOLOGY
卷 14, 期 -, 页码 -

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2023.1122065

关键词

renal cell carcinoma; long non-coding RNAs; metabolism; biomarkers; tumor progression

向作者/读者索取更多资源

This review summarizes the metabolic regulatory mechanisms of long non-coding RNAs (lncRNAs) in the progression of renal cell carcinoma (RCC), especially their roles in glucose metabolism, lipid metabolism, amino acid metabolism, and mitochondrial dynamics. It also discusses the clinical applications of lncRNAs targeting metabolism in RCC therapy. Accumulating evidence shows that lncRNAs participate in the occurrence and progression of RCC, achieved through the lncRNA-miRNA-mRNA axis. This study provides new targets and approaches for early clinical diagnosis, treatment, and prognosis of RCC.
Renal cell carcinoma (RCC) is the most frequent renal malignancy in the world, and its incidence is increasing year by year. RCC is a well-known drug resistant tumor, and the treatment methods are limited. Most patients with RCC are discovered at the advanced stage, and thus have poor prognosis even after treatment. Therefore, it is very urgent to find new markers for the diagnosis and treatment of RCC. Accumulating evidence shows that lncRNAs participate in the occurrence and progression of RCC, which is achieved by the lncRNA-miRNA-mRNA axis. It is widely known that metabolic defect is an essential pathogenesis in RCC. As is the case with other tumors, RCC can satisfy the demands of cancerous cells for uncontrolled proliferation through aerobic glycolysis. However, whether lncRNAs can modulate RCC progression through metabolic pathway is still not clarified. Taken together, this review mainly summarized the metabolic regulatory mechanisms of lncRNAs in RCC progression, especially their roles in glucose metabolism, lipid metabolism, amino acid metabolism and mitochondrial dynamics, as well as the clinical applications of lncRNAs via targeting metabolism in RCC therapy. It will provide the new targets and approaches for early clinical diagnosis, treatment and prognosis of RCC.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据